Trials / Completed
CompletedNCT06371326
A Study of ZT002 Injection in Participants With Overweight or Obesity
A Randomized, Double-blind, Placebo-controlled, Multiple-ascending-dose Phase Ic Study Evaluating the Safety, Tolerability, and Pharmacokinetics of ZT002 Injection in Participants With Overweight or Obesity
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Beijing QL Biopharmaceutical Co.,Ltd · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
This study will comprise a randomized, double-blind, placebo-controlled, multiple-ascending-dose, safety, tolerability, and pharmacokinetics study of ZT002 in participants with Overweight or Obesity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ZT002 Injection | Participants will receive ZT002 by subcutaneous (SC) injection. |
| DRUG | Placebo | Participants will receive Placebo by subcutaneous (SC) injection. |
Timeline
- Start date
- 2023-11-21
- Primary completion
- 2024-04-15
- Completion
- 2024-10-17
- First posted
- 2024-04-17
- Last updated
- 2026-01-16
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06371326. Inclusion in this directory is not an endorsement.